NCT03779672 - Memantine for Epileptic Encephalopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

November 8, 2021

Study Completion Date

February 8, 2022

Conditions

Epileptic Encephalopathy, Childhood-Onset

Interventions

DRUG

Memantine Hydrochloride 10 mg

"* Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps"

Trial Locations (1)

H4A 3J1

Children Hospital - MUHC, Montreal

All Listed Sponsors

lead

Kenneth Myers, MD

OTHER